They’re meant to save money for the health care system, carve into pharma’s profits, and finally rid your television of some annoying commercials. But what are biosimilars, and where’s the revolution they were promised to bring?
In short, biosimilars are cheaper versions of blockbuster drugs that can be sold as soon as those blockbusters lose patent protection. They’re conceptually similar to generics — the low-cost pills available in pharmacies around the world — but with a vastly important distinction: Biosimilars mimic biologic drugs, which are crafted from living cells, and that means they’re not technically identical the way off-brand atorvastatin is identical to Lipitor.
Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
Ohhh, I was digging this until he mentioned that “Humira is an antibody made by bacteria”… it is made in mammalian CHO cells. You would have been better off just saying cells…